PUBLISHER: Grand View Research | PRODUCT CODE: 1493251
PUBLISHER: Grand View Research | PRODUCT CODE: 1493251
The global lung cancer liquid biopsy market size is anticipated to reach USD 2.35 billion by 2030, growing at a CAGR of 13.3% from 2024 to 2030, according to a new report by Grand View Research, Inc. Liquid biopsies offer a non-invasive alternative to traditional tissue biopsies, enabling earlier detection of lung cancer. The diagnostics industry is moving towards precision medicine, which requires accurate and comprehensive diagnostic tools. Liquid biopsies offer a promising solution for providing information for personalized treatment plans.
Factors such as late detection and high mortality rates result in a decline in the overall survival rate. Lifestyle habits such as cigarette smoking and tobacco exposure are some of the significant risk factors, contributing to approximately 80% of the total lung cancer cases worldwide. According to the World Health Organization (WHO), in 2020, 22.3% of the world's population consumed tobacco, which constitutes 36.7% of men and 7.8% of the total women. It also states that tobacco causes the deaths of more than 8 million people each year, including an estimated 1.3 million passive smokers.
Companies are launching newer technologies and products to screen lung cancers. For instance, Delfi Diagnostics launched its blood test to screen for lung cancer in October 2023. This increasing number of launches involving newer launches is anticipated to propel the market.